WO2004046175A1 - Vaccine - Google Patents

Vaccine Download PDF

Info

Publication number
WO2004046175A1
WO2004046175A1 PCT/EP2003/012793 EP0312793W WO2004046175A1 WO 2004046175 A1 WO2004046175 A1 WO 2004046175A1 EP 0312793 W EP0312793 W EP 0312793W WO 2004046175 A1 WO2004046175 A1 WO 2004046175A1
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
polynucleotide
protein
core
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/012793
Other languages
English (en)
French (fr)
Inventor
Sara Brett
Paul Andrew Hamblin
Louise Ogilvie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/534,774 priority Critical patent/US20060135451A1/en
Priority to JP2004552615A priority patent/JP2006518331A/ja
Priority to MXPA05005202A priority patent/MXPA05005202A/es
Priority to AU2003288072A priority patent/AU2003288072A1/en
Priority to CA002504715A priority patent/CA2504715A1/en
Priority to EP03779938A priority patent/EP1560844A1/en
Priority to NZ539999A priority patent/NZ539999A/en
Priority to BR0316244-3A priority patent/BR0316244A/pt
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of WO2004046175A1 publication Critical patent/WO2004046175A1/en
Priority to IS7831A priority patent/IS7831A/is
Priority to NO20052149A priority patent/NO20052149L/no
Anticipated expiration legal-status Critical
Priority to US12/471,772 priority patent/US20090232847A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the polynucleotides encoding each antigen are present in the same expression vector or plasmid such that expression of the HCV proteins occurs in the same cell.
  • the polynucleotides encoding the HCV proteins may be in a single expression cassette, or in multiple in series expression cassettes within the same polynucleotide vector.
  • codon usage patterns of organisms are highly non-random. Different species show a different bias in their codon selection and, furthermore, utilisation of codons may be markedly different in a single species between genes which are expressed at high and low levels. This bias is different in viruses, plants, bacteria and mammalian cells, and some species show a stronger bias away from a random codon selection than others. For example, humans and other mammals are less strongly biased than certain bacteria or viruses. For these reasons, there is a significant probability that a mammalian gene expressed in E.coli or a viral gene expressed in mammalian cells will have an inappropriate distribution of codons for efficient expression.
  • HGMV IE HGMV IE
  • a polynucleotide of the invention is operably linked to a control sequence which is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector.
  • the term "operably linked” refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.
  • a regulatory sequence such as a promoter, "operably linked" to a coding sequence is positioned in such a way that expression of the coding sequence is achieved under conditions compatible with the regulatory sequence.
  • An expression cassette is an assembly which is capable of directing the expression of the sequence or gene of interest.
  • the expression cassette comprises control elements, such as a promoter which is operably linked to the gene of interest.
  • the DNA vaccines of the present invention stimulate an effective immune response, typically CD4+ and CD8+ immunity against the HCV antigens .
  • an effective immune response typically CD4+ and CD8+ immunity against the HCV antigens .
  • a broad range of epitopes Preferably against a broad range of epitopes. It is preferred in a therapeutic setting that liver fibrosis and/or inflammation be reduced following vaccination.
  • N.B. Numbering is according to position in polyprotein for J4L6 isolate.
  • each new polynucleotide sequence incorporating codon optimisation, enzymatic knockout mutations, and consensus mutations, were divided into regions of 40-60 nucleotides, with a 20 nucleotide overlap. These regions were synthesised commercially and the polynucleotide generated by an oligo assembly PCR method.
  • the outer forward and reverse PCR primers for each polynucleotide illustrating unique restriction endonuclease sites used for cloning, are outlined below: HCV Core

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PCT/EP2003/012793 2002-11-15 2003-11-13 Vaccine Ceased WO2004046175A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
NZ539999A NZ539999A (en) 2002-11-15 2003-11-13 A polynucleotide vaccine comprising a polynucleotide sequence that encodes the HCV core protein and a polynucleotide that encodes at least one other HCV protein
MXPA05005202A MXPA05005202A (es) 2002-11-15 2003-11-13 Vacuna.
AU2003288072A AU2003288072A1 (en) 2002-11-15 2003-11-13 Vaccine
CA002504715A CA2504715A1 (en) 2002-11-15 2003-11-13 Vaccine
EP03779938A EP1560844A1 (en) 2002-11-15 2003-11-13 Hepatitis c vaccine
US10/534,774 US20060135451A1 (en) 2002-11-15 2003-11-13 Vaccine
JP2004552615A JP2006518331A (ja) 2002-11-15 2003-11-13 ワクチン
BR0316244-3A BR0316244A (pt) 2002-11-15 2003-11-13 Vacina de polinucleotìdeo, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina de polinucleotìdeo
IS7831A IS7831A (is) 2002-11-15 2005-04-28 Bóluefni
NO20052149A NO20052149L (no) 2002-11-15 2005-05-02 Polynukleotidvaksine omfattende sekvens som koder for hepatitt C-virus protein.
US12/471,772 US20090232847A1 (en) 2002-11-15 2009-05-26 Immunogenic compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine
GB0226722.7 2002-11-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/471,772 Continuation US20090232847A1 (en) 2002-11-15 2009-05-26 Immunogenic compositions

Publications (1)

Publication Number Publication Date
WO2004046175A1 true WO2004046175A1 (en) 2004-06-03

Family

ID=9947928

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2003/012793 Ceased WO2004046175A1 (en) 2002-11-15 2003-11-13 Vaccine
PCT/EP2003/012830 Ceased WO2004046176A1 (en) 2002-11-15 2003-11-13 Vaccine against hcv

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/012830 Ceased WO2004046176A1 (en) 2002-11-15 2003-11-13 Vaccine against hcv

Country Status (21)

Country Link
US (4) US20060135451A1 (https=)
EP (2) EP1560844A1 (https=)
JP (2) JP2006524181A (https=)
KR (2) KR20050085009A (https=)
CN (2) CN1738834A (https=)
AR (1) AR041964A1 (https=)
AU (2) AU2003288072A1 (https=)
BR (2) BR0316291A (https=)
CA (2) CA2504715A1 (https=)
CO (1) CO5700833A2 (https=)
GB (1) GB0226722D0 (https=)
IS (2) IS7830A (https=)
MA (2) MA27700A1 (https=)
MX (2) MXPA05005203A (https=)
NO (2) NO20052136L (https=)
NZ (2) NZ539998A (https=)
PL (2) PL376967A1 (https=)
RU (2) RU2323744C2 (https=)
TW (1) TW200502246A (https=)
WO (2) WO2004046175A1 (https=)
ZA (2) ZA200503802B (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
JP2009522368A (ja) * 2006-01-04 2009-06-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｈｃｖ特異的なｔ細胞の活性化
US7625569B2 (en) 2004-10-18 2009-12-01 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8158602B2 (en) 2000-08-17 2012-04-17 Chrontech Pharma Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
ATE556136T1 (de) * 2006-03-09 2012-05-15 Transgene Sa Nichtstrukturelles hcv-fusionsprotein
WO2008094200A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
US9439959B2 (en) 2006-07-27 2016-09-13 Takeda Vaccines, Inc. Chimeric influenza virus-like particles
KR100759106B1 (ko) * 2007-02-14 2007-09-19 이화여자대학교 산학협력단 초미세 전기기계 시스템 미러에서 미러 판을 정전 구동부와 결합하는 방법
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
RU2370776C2 (ru) * 2007-11-08 2009-10-20 Общество с ограниченной ответственностью "Диагностические Центры "Алкор Био" Набор антигенов для раздельного выявления антител к структурным и неструктурным белкам вируса гепатита с
CA2722423A1 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
JP2011529077A (ja) * 2008-07-24 2011-12-01 アデュロ バイオテック Ｃ型肝炎の治療のための組成物および方法
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
WO2011056899A2 (en) 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
CN102233137B (zh) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
CA2901501C (en) 2013-02-21 2023-03-07 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
CN119504957B (zh) * 2025-01-16 2025-04-25 中山大学 一种佐剂及其在制备疫苗中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010997A1 (en) * 1994-10-05 1996-04-18 Apollon, Inc. Hepatitis virus vaccines
WO1996037606A1 (en) * 1995-05-22 1996-11-28 Bionova Corporation Compositions and methods for the diagnosis of, and vaccination against, hepatitis c virus (hcv)
WO1997047358A1 (en) * 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
WO2001004149A1 (en) * 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis c virus proteins
WO2001030812A2 (en) * 1999-10-27 2001-05-03 Chiron Corporation Activation of hcv-specific t cells
WO2001038360A2 (en) * 1999-11-24 2001-05-31 Chiron Corporation Novel hcv non-structural polypeptide
US20020141974A1 (en) * 1992-02-04 2002-10-03 Jolly Douglas J. Hepatitis therapeutics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
NZ227011A (en) * 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
CA2070952A1 (en) * 1991-06-11 1992-12-12 Makoto Seki Gene of hepatitis c virus or fragment thereof, polypeptide encoded by the same
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020141974A1 (en) * 1992-02-04 2002-10-03 Jolly Douglas J. Hepatitis therapeutics
WO1996010997A1 (en) * 1994-10-05 1996-04-18 Apollon, Inc. Hepatitis virus vaccines
WO1996037606A1 (en) * 1995-05-22 1996-11-28 Bionova Corporation Compositions and methods for the diagnosis of, and vaccination against, hepatitis c virus (hcv)
WO1997047358A1 (en) * 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
WO2001004149A1 (en) * 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis c virus proteins
WO2001030812A2 (en) * 1999-10-27 2001-05-03 Chiron Corporation Activation of hcv-specific t cells
WO2001038360A2 (en) * 1999-11-24 2001-05-31 Chiron Corporation Novel hcv non-structural polypeptide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALVAREZ-OBREGON J C ET AL: "A truncated HCV core protein elicits a potent immune response with a strong participation of cellular immunity components in mice", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 28-29, 16 July 2001 (2001-07-16), pages 3940 - 3946, XP004247549, ISSN: 0264-410X *
MOORMAN JONATHAN P ET AL: "The C-terminal region of hepatitis C core protein is required for Fas-ligand independent apoptosis in Jurkat cells by facilitating Fas oligomerization.", VIROLOGY, vol. 312, no. 2, 1 August 2003 (2003-08-01), pages 320 - 329, XP004446041, ISSN: 0042-6822 (ISSN print) *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158602B2 (en) 2000-08-17 2012-04-17 Chrontech Pharma Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US8163547B2 (en) 2000-08-17 2012-04-24 Chrontech Pharma Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
EP1567190B1 (en) * 2002-11-26 2013-04-10 ChronTech Pharma AB A hepatitis c virus codon optimized non-structural ns3/4a fusion gene
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US7625569B2 (en) 2004-10-18 2009-12-01 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US7632511B2 (en) 2004-10-18 2009-12-15 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8007816B2 (en) 2004-10-18 2011-08-30 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8388980B2 (en) 2004-10-18 2013-03-05 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8821892B2 (en) 2004-10-18 2014-09-02 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
JP2009522368A (ja) * 2006-01-04 2009-06-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｈｃｖ特異的なｔ細胞の活性化
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection

Also Published As

Publication number Publication date
RU2005113691A (ru) 2006-01-27
BR0316244A (pt) 2005-10-04
RU2363492C2 (ru) 2009-08-10
ZA200503802B (en) 2006-08-30
NO20052149D0 (no) 2005-05-02
MXPA05005202A (es) 2006-01-27
IS7831A (is) 2005-04-28
CO5700833A2 (es) 2006-11-30
US20060135451A1 (en) 2006-06-22
JP2006524181A (ja) 2006-10-26
BR0316291A (pt) 2005-10-11
KR20050085009A (ko) 2005-08-29
JP2006518331A (ja) 2006-08-10
AU2003288072A1 (en) 2004-06-15
PL376967A1 (pl) 2006-01-23
NZ539999A (en) 2008-03-28
IS7830A (is) 2005-04-28
RU2005113692A (ru) 2006-01-27
CA2504715A1 (en) 2004-06-03
CN1738834A (zh) 2006-02-22
AU2003288084A1 (en) 2004-06-15
CN1738833A (zh) 2006-02-22
AR041964A1 (es) 2005-06-01
NO20052149L (no) 2005-07-11
RU2323744C2 (ru) 2008-05-10
ZA200503803B (en) 2006-08-30
US20090232847A1 (en) 2009-09-17
NO20052136D0 (no) 2005-05-02
US20090104231A1 (en) 2009-04-23
NZ539998A (en) 2008-04-30
TW200502246A (en) 2005-01-16
KR20050085010A (ko) 2005-08-29
US20060246090A1 (en) 2006-11-02
GB0226722D0 (en) 2002-12-24
MA27700A1 (fr) 2006-01-02
MXPA05005203A (es) 2006-01-27
WO2004046176A1 (en) 2004-06-03
EP1560845A1 (en) 2005-08-10
MA27699A1 (fr) 2006-01-02
NO20052136L (no) 2005-07-11
CA2504654A1 (en) 2004-06-03
PL376882A1 (pl) 2006-01-09
EP1560844A1 (en) 2005-08-10

Similar Documents

Publication Publication Date Title
US20090232847A1 (en) Immunogenic compositions
KR100874552B1 (ko) 코돈-최적화 파필로마 바이러스 서열
US6355247B1 (en) Nucleic acid immunization using a virus-based infection/transfection system
AU2001275695A1 (en) Codon-optimized papilloma virus sequences
US7074410B2 (en) Modified HCV peptide vaccines
JP2007537757A (ja) 切断ｃ型肝炎ｎｓ５ドメインおよびこれを含む融合タンパク質
CN1289339A (zh) 采用丙型肝炎病毒非结构蛋白进行的基因免疫
EP1448223B1 (en) Thymosin augmentation of genetic immunization
AU2002360315B2 (en) Thymosin augmentation of genetic immunization
AU741876B2 (en) Hepatitis virus vaccines
AU2002360315A1 (en) Thymosin augmentation of genetic immunization
AU2298602A (en) Hepatitis virus vaccines
CN101255434A (zh) 疫苗

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 724/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 168275

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2504715

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003288072

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005/03803

Country of ref document: ZA

Ref document number: 200503803

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 539999

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004552615

Country of ref document: JP

Ref document number: PA/a/2005/005202

Country of ref document: MX

Ref document number: 376882

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 1020057008794

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003779938

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 05056623

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: DZP2005000199

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 2005113691

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1200500814

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 20038A8865X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003779938

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057008794

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0316244

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 1-2005-500885

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2006135451

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10534774

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10534774

Country of ref document: US